Merck & Co. (MRK)
(Delayed Data from NYSE)
$125.92 USD
+1.54 (1.24%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $126.14 +0.22 (0.17%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth F Momentum C VGM
Brokerage Reports
0 items in cart
Merck & Co., Inc. [MRK]
Reports for Purchase
Showing records 361 - 380 ( 398 total )
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Griffin Securities Updates Coverage on Ligand Pharma. (LGND)
Provider: GRIFFIN SECURITIES, INC.
Analyst: MARKEY K
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Specialty Pharmaceuticals Short Interest Analysis
Provider: AURIGA USA
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company Leveraged 2% Fourth Quarter Sales Growth into a Double-Digit Earnings Gain
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Technical Takeaways: Bullish Sector Rotation Continues; Pharmaceutical ETF may be Topping.
Provider: AURIGA USA
Analyst: ALBANESE G
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Technical Takeaways: Bullish Sector Rotation Continues; Pharmaceutical ETF may be Topping.
Provider: AURIGA USA
Analyst: ALBANESE G
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Broad-based Worldwide Third Quarter Revenue Growth
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Company: Merck & Co., Inc.
Industry: Large Cap Pharmaceuticals
Management Pursuing Additional Cost Savings to Sustain Earnings
Provider: J.J.B. Hilliard, W.L. Lyons
Analyst: O'NEIL S